
STANDARD OPERATING PROCEDURE

Continuing Review

1 PURPOSE

- 1.1** This procedure establishes the process to conduct continuing review of approved human subject research protocols for purposes of renewal of the IRB approval period.
- 1.1.1** The process begins when the Principal Investigator (PI) submits documentation for consideration of renewal of the IRB approval period to the IRB Office.
 - 1.1.2** The process ends with the notification of study closure from the PI or IRB determination of the approval period resulting in:
 - 1.1.2.1** Renewal of IRB approval period for an IRB-determined time frame
 - 1.1.2.2** Renewal Disapproval, or
 - 1.1.2.3** Study Expiration
 - 1.1.2.3.1** All research-related activity must cease unless the IRB deems that it is in the best interests of individual subjects to continue participating in the research interventions or interactions.

2 POLICY

- 2.1** The IRB must conduct continuing review of applicable approved human subject research protocols for purposes of renewal of the IRB approval period. Review must occur within (1) one year from the date of last approval. The IRB may conduct continuing review using the expedited procedure for research that otherwise would not require continuing review under [46.109\(f\)\(1\)](#), but these continuing review activities must be documented and rationale for this review provided under [46.115\(a\)\(3\)](#).

The determination of the length of the approval period, if applicable, is documented in the reviewer checklist and if reviewed by the convened board, in the minutes. The study expires on the expiration date specified on the approval letter and consent document(s), as applicable. Continuing review must occur prior to the expiration date.

For ease of tracking, the expiration date of applicable studies is set for the first day of the month of the following year that approval was granted (i.e., if approval is granted on June 14, 2022 the expiration date will fall on the June 1, 2023). Therefore, when the IRB grants approval for one year at the time of each continuing review, and the IRB performs continuing review and re-approves (with or without conditions) the research within 30

days before the IRB approval period expires, the IRB may retain the anniversary of the expiration date of the initial IRB approval as the expiration date of each subsequent one-year approval period. For example, if an IRB conducts initial review of a research project and approves it without conditions on October 1, 2020 for one year, the IRB may conduct its first continuing review anytime between September 1 and October 1, 2021, and re-approve the research for another one-year period that expires on October 1, 2021. The same timing may be applied to each subsequent continuing review until the research activities involving human subjects are completed. If continuing review and re-approval does not occur before the expiration date of IRB approval for all applicable studies, all research-related activity must cease unless the IRB finds that it is in the best interests of individual subjects to continue participating in the research interventions or interactions. Continuing review of applicable studies is required until the study is closed in the Mentor IRB system.

Review of a change in a protocol (i.e. modification or amendment) does not alter the date by which continuing review must occur because continuing review is review of the full protocol, not simply a change to it.

- 2.1.1** Research studies that require continuing review include:
 - 2.1.1.1** All research subject to the pre-2018 Common Rule Requirements (approved on or prior to January 20, 2019)
 - 2.1.1.2** All Research subject to FDA regulation
 - 2.1.1.3** Non FDA-regulated research initially approved by the convened IRB (full board) AND subject to the Final Rule [45 CFR 46](#) (approved after January 20, 2019)

- 2.1.2** Research that does not require continuing review (subject to the Final Rule [45 CFR 46](#)) include:
 - 2.1.2.1** Research that has progressed to the point where it only involves one or both of the following criteria:
 - 2.1.2.1.1** Data analysis, including analysis of identifiable private information or identifiable biospecimens
 - 2.1.2.1.2** Accessing follow-up clinical data from procedures that subjects would undergo as part of clinical care
 - 2.1.2.2** Minimal risk research originally approved by the expedited review mechanism prior to January 20, 2019, and involves one or both of the following criteria:
 - 2.1.2.2.1** Exempt research requiring limited IRB review
 - 2.1.2.2.2** Transitioned Research that meets the criteria set forth in 3.1.2.1, 3.1.2.2, and 3.1.2.3 of this Standard Operating Procedure
 - 2.1.2.2.2.1** Research deemed by the chairman as Transitioned Research applies to either:
 - 2.1.2.2.2.1.1** Full board studies that no longer involve subject intervention/interaction; the IRB will evaluate the need for continuing review at

the time of the next scheduled continuing review

2.1.2.2.1.2 Accessing follow-up clinical data from procedures that subjects would undergo as part of clinical care, or data analysis including analysis of identifiable private information or identifiable biospecimens

2.1.2.3 Studies (minimal risk research) originally approved by the expedited review mechanism under the pre-2018 Common Rule Requirements on or after to January 20, 2019

2.2 TCH IRB is responsible for continued oversight of all human subjects' research, even when formal continuing review is not required. Toward this end, the IRB has implemented a brief "study status update" process to ascertain the status of each protocol that does not require formal continuing review to verify that no unapproved changes or unreported problems have occurred. The status check occurs annually. Researchers receive notification of an upcoming status check in advance of the annual period end-date.

3 RESPONSIBILITY

3.1 Principal Investigator (PI): PI must submit required continuing review documentation or notification of study closure prior to expiration in the timeframe set forth by this Standard Operating Procedure.

3.2 IRB Office: Facilitates appropriate review of all submitted documentation and relays IRB determination to PI

3.3 IRB Chair: Serves as primary reviewer or assigns designee

3.4 IRB: Reviews submission documentation and makes determination regarding renewal of IRB approval period

4 PROCEDURE

4.1 The Principal Investigator, or authorized designee, performs the following:

4.1.1 Completes and submits a continuation form in Mentor IRB for review by the due date in Mentor IRB ensuring the following documents/files are attached for consideration:

4.1.1.1 Current consent document for studies which remain active and enrolling subjects, or which are closed to further enrollment but remain in the process of reconsenting subjects

4.1.1.2 FCOI Affidavit for all investigators and other key research personnel

4.1.1.3 Protocol Deviation Log (IND, IDE, and HDE studies only) as applicable, and

- 4.1.2 Ensures all investigators and other key research personnel's Investigator Qualifications are still current in Mentor IRB, such as:
 - 4.1.2.1 CITI Transcripts (completed within the last three years)
 - 4.1.2.2 CV or Resumé
 - 4.1.2.3 Medical License and/or Nursing License, if applicable

- 4.2 IRB Office performs the following:
 - 4.2.1 Reviews all submitted documentation to assure completeness of the submission
 - 4.2.2 Makes a determination regarding whether the research qualifies for expedited review or review by the convened IRB
 - 4.2.3 Assigns the submission for review in Mentor IRB to either the:
 - 4.2.3.1 IRB Chair or designee for expedited review, or
 - 4.2.3.2 Full Board Panel for IRB members for convened review
 - 4.2.4 Documents IRB determination in either the:
 - 4.2.4.1 Exempt/Expedited Panel for research approved by expedited review for review by the convened board at the next scheduled meeting; or
 - 4.2.4.2 the meeting minutes for research approved by the convened board; then
 - 4.2.4.2.1 Issues one of the following determination letters in Mentor IRB:
 - 4.2.4.2.1.1 Approval letter and any stamped approved consent document(s) to the principal investigator and any research coordinator
 - 4.2.4.2.1.2 Approval with contingencies letter and stamped approved consent document(s) to the principal investigator and any research coordinator, or
 - 4.2.4.2.1.3 Disapproval letter with IRB rationale to the principal investigator, any research coordinator, department head, and institutional official
 - 4.2.5 Updates Mentor IRB protocol record with determination, approval date and expiration date
 - 4.2.6 Ensures all approved documents are appropriately linked on the main protocol page in Mentor IRB

- 4.3 IRB Chair or designee performs the following:
 - 4.3.1 Primary review or appoints an experienced IRB member as designee to perform primary review utilizing the IRB: Continuing Review Checklist in Mentor IRB
 - 4.3.1.1 For studies that are applicable for the expedited review mechanism:
 - 4.3.1.1.1 Makes an approval determination in Mentor IRB

